52 results about "Tuberculosis incidence" patented technology

The invention relates to Ag85B-ESAT-6 embedded protein vaccine, which is matched with agent MPL-TDM to immunize mouse, to make the IgG2a / IgG1 and IFN- gamma discharge higher then Ag85B-ESAT-6 fusion protein, while later one can generate same protective effect as BCG after infected by bacillus tubercle.

The invention discloses an application of enniatine compound for preparing anti-drug-resistant tubercle bacillus drugs; the enniatine compound has a general formula showed by a formula (I); aiming atthe conditions that tuberculosis has high morbidity at present, mycobacterium tuberculosis has multiple drug-resistant strains and human immune deficiency virus is infected doubly, so as to lead the tuberculosis morbidity and mortality to be on the rise, the invention provides a new application of the enniatine compound on the anti-drug-resistant tubercle bacillus by finding that the enniatine compound has strong anti-drug-resistant tubercle bacillus activity, thereby not only providing a new beneficial tool for the treatment of the drug-resistant tubercle bacillus, but also expanding the application range of the enniatine compound. In addition, the enniatine compound is derived from ocean mangrove endophytic fungi, the raw material is plentiful, and the collection and cultivation of the raw material are easy, the purification is easy and the cost is low, and the breeding cycle is short, thereby being large-scale industrial production.

The invention discloses an improved recombinant bacillus calmetter Guerin (BCG), belonging to the technical field of new medicaments. The immune protecting effect of a unique anti-tuberculosis vaccine BCG for tuberculosis is not exact and the tuberculosis morbidity gradually rises over the past 10 years. Therefore, the development of a more effective anti-tuberculosis vaccine is important. Gene sequences of mycobacterium tuberculosis ESAT6 and Ag85A are inserted into shuttle plasmids of colon bacillus-mycobacterium tuberculosis for forming recombinant plasmids; and the recombinant plasmids are converted into the BCG to form a recombinant anti-tuberculosis vaccine. Proved by research, the recombinant BCG is used for expressing introduced foreign genes and is a novel anti-tuberculosis vaccine.

The invention relates to a recombinant bacillus Calmette-Guerin vaccine and its preparation method, wherein tuberculosis mycobacterium ag85b, esat-6 and IFN-gamma gene sequences are inserted into colibacillus-tuberculosis mycobacterium shuttle plasmids to form recombinant plasmid, and are transformed into BCG to form recombinant tuberculosis vaccine. The recombinant vaccine can be used for prevention and treatment of tuberculosis with better immunological effects than BCG.

The invention discloses application of Cyanogramide to preparation of medicine for resisting mycobacterium tuberculosis. Targeting the current situation that high morbidity of tuberculosis and appearance of mycobacterium tuberculosis multi-drug-resistant strains lead to a rising trend of the tuberculosis morbidity and the death rate, it is found that Cyanogramide has remarkable activity in inhibiting mycobacterium tuberculosis and then has a very good application prospect. The usage of Cyanogramide in preparing the medicine for treating and resisting mycobacterium tuberculosis is disclosed for the first time; due to the fact that the framework type is brand new and the activity of Cyanogramide in inhibiting mycobacterium tuberculosis is too strong to imagine, it is impossible to give any revelation by other compounds, and Cyanogramide has outstanding substantive characteristics; meanwhile, Cyanogramide apparently has remarkable progress when applied to prevention and treatment of mycobacterium tuberculosis infection.

The invention discloses an application of a quinine compound in preparing anti-tubercle bacillus drugs. A structure general formula of the quinine compound of the invention is shown in a formula (1), wherein R is H or OH. In the invention, aiming to current situations that the current tuberculosis has high morbidity, and multidrug-resistant tuberculosis (TB) strains of tubercle bacillus occur so that the morbidity and mortality of the tuberculosis are in a rising trend, and according to characteristics of anti-tubercle bacillus and tolerance tubercle bacillus activities of the quinine compound, the quinine compound is used for preparing the anti-tubercle bacillus drugs. The quinine compound of the invention is derived from marine microorganisms, is easy to be extracted, has low cost and wide application prospect, and can be used for preparing the anti-tubercle bacillus drugs.

This invention is associated with the gene engineering field and tuberculosis vaccines field. In recent decades, the increase of tuberculosis drug resistant strain and the coinfection of mycobacterium tuberculosis and HIV lead the increase of incidence of tuberculosis, and made it the second killer of human after HIV. Recently, the only tuberculosis vaccines used globally is BCG. This invention inserts the most important protective antigen gene of mycobacterium tuberculosis and missed mycobacterium tuberculosis gene in BCG to the multi-cloning coliform - mycobacterium tuberculosis shuttle-plasmid multiple cloning sites to form recombined plasmid and transforms it to the BCG to form recombined tuberculosis vaccines. The result of experiment shows that, compared with BCG vaccine, the protective antigen can express more efficient, the original missing Rv3425 antigen also get expressed, and the induced IFN- gamma expression also increased significently. This indicates that the recombined tuberculosis vaccines can induce higher cell immunity level than BCG.

The invention discloses an application of polyflavanostilbene A in preparation of anti-tuberculosis bacteria medicaments. The invention is designed against the current situation that the incidence rate and the mortality rate of tuberculosis are in a rising trend due to high incidence rate of the tuberculosis and the appearance of multiple-resistant strains of tuberculosis bacteria and finds that the polyflavanostilbene A has significant inhibition activity against the tuberculosis bacteria and further has good application prospects. The use of the polyflavanostilbene A in the preparation of the anti-tuberculosis bacteria medicaments, disclosed by the invention, belongs to the first disclosure, as the framework type belongs to the brand new framework type, the strong inhibition activity against the tuberculosis bacteria is unexpected, the possibility of giving any notices by other compounds does not exist, and the polyflavanostilbene A has prominent substantial characteristics; and simultaneously, the polyflavanostilbene A obviously has a significant progress in control of infection of the tuberculosis bacteria.

The invention discloses an application of aphanamixoid A in preparing an antituberculosis medicament. Regarding the current situation that the tuberculosis incidence rate and death rate are in a rising trend due to the high incidence rate of current tuberculosis and occurrence of multiple-resistant strain of mycobacterium tuberculosis, the invention discovers that aphanamixoid A has remarkable activity of inhibiting tuberculosis, and has a high application prospect. The application of aphanamixoid A in preparing a medicament for treating tuberculosis belongs to first disclosure, which has prominent substantial characteristics because the frame model belongs to a brand-new frame model, and has unexpectedly strong inhibiting activity to tuberculosis without the possibility of giving any revelation by other compounds, and the prevention and treatment of aphanamixoid A for tuberculosis infection has a remarkable progress.

The invention discloses an application of Myriberine A in preparing antituberculous medicines. The application of the Myriberine A aims at current situations that high tuberculosis incidence and appearance of multi-drug resistant strains of tubercle bacillus result in the rising tendency in the incidence and mortality rate of the tuberculosis, and the Myriberine A is found to have remarkable tubercle bacillus inhibitory activity and a good application prospect. The application of the Myriberine A in preparing the antituberculous medicines is disclosed for the first time. The framework type is a brand-new framework type, and therefore the Myriberine A has unexpected tubercle bacillus inhibitory activity. The Myriberine A has prominent substantive features and is impossibly revealed by other compounds, and has remarkable progresses when used for preventing and treating tubercle bacillus infection.

The invention relates to a recombinant tuberculosis vaccine, a preparation method and an application thereof. The vaccine can enhance the special I type cellular immunity of an inoculated crowd body effectively and strengthen the immune protective force of the inoculated crowd on mycobacterium tuberculosis. The vaccine matched with a bcg vaccine in use can change the condition that single use of the BCG is non-effective to part of individuals and crowds infected with mycobacterium tuberculosis, so that the aim of reducing the tuberculosis incidence rate is achieved.

The invention discloses application of gypensapogenin A to preparation of anti-tubercle bacillus drugs. According to the high tubercle bacillus morbidity and the emergence of mycobacterium tuberculosis multiple-resistant strain, the tubercle bacillus morbidity and mortality are one the rise; and gypensapogenin A has remarkable tubercle bacillus suppression activity and good application prospect. The application of gypensapogenin A to the preparation of the anti-tubercle bacillus drugs is firstly publicized, the skeleton type is brand-new, the tubercle bacillus suppression activity is unexpectedly strong and the possibility of giving any revelation by other compounds does not exist, so that prominent substantive features are provided and a remarkable progress in the prevention and treatment of the tubercle bacillus infection is made at the same time.

The invention discloses a novel use of pyrvinium pamoate in preparation of anti-mycobacterium tuberculosis drugs. The invention is directed at a current situation that incidence and mortality of tuberculosis tend to rise due to high incidence of tuberculosis as well as serious drug resistance and multiple drug-resistant drugs caused by mycobacterium tuberculosis at present; 1280 drug libraries provided by MicroSource Discovery Systems, Inc. (USA) are utilized to identify that the pyrvinium pamoate has activities in inhibition of various mycobacterium tuberculosis and drug-resistant bacteria. The pyrvinium pamoate is a drug approved by FDA of US for treating enterobiasis and human ankylosing chromosome disease; the safety and pharmacokinetic properties of the pyrvinium pamoate are evaluated in humans and animals, so that the anti-mycobacterium tuberculosis effect can be detected directly in clinical practice, avoids a shortcoming of too long approval time of new drugs, and has a broad application prospect in treatment of tuberculosis and extrapulmonary tuberculosis (such as intestinal tuberculosis, etc.) caused by mycobacterium tuberculosis.

The invention discloses an application of Aspeverin in preparation of medicaments for resisting tubercle bacillus. According to the application disclosed by the invention, Aspeverin is found to have an activity of remarkably inhibiting tubercle bacillus, and a great application prospect, aiming at the current situations that the morbidity and mortality of tuberculosis are on the rise due to the high morbidity of tuberculosis and the occurrence of multi-drug-resistant mycobacterium tuberculosis strains at present. The application of the Aspeverin in preparation of medicaments for resisting tubercle bacillus is disclosed for the first time; the Aspeverin has a new framework type, and an unexpectedly high inhibition activity on tubercle bacillus, so that the possibility of giving any revelation by other compounds is avoided; and the Aspeverin has prominent substantive features, and an obviously remarkable improvement in case of being used for preventing and treating tubercle bacillus infection.

The invention discloses application of Foveospirolide in preparation of tubercle bacillus treating and resisting medicine. For the situation that current tuberculosis morbidity is high, mycobacterium tuberculosis multiple-resistant strains appear and tuberculosis morbidity and the death rate are increased, it is found that Foveospirolide has remarkable activity for restraining tubercle bacillus and has quite good application prospects. The application of Foveospirolide in preparation of tubercle bacillus treating and resisting medicine is disclosed for the first time; due to the fact that the framework type belongs to a brand-new framework type, Foveospirolide is unexpectedly high in tubercle bacillus restraining activity, no other compounds give any prompts, remarkable substantive features are achieved, and meanwhile Foveospirolide obviously has a remarkable progress for preventing and treating tuberculous infection.

The invention discloses application of Flabelliferin B in preparing anti-tuberculosis drugs. The invention, in accordance with the current situation that the morbidity and mortality of tuberculosis are on the rise due to the high morbidity of the tuberculosis and the appearance multiple drug-resistant strains of the tuberculosis at present, discovers that the Flabelliferin B has an activity of significantly inhibiting tuberculosis, and the Flabelliferin B is good in application prospect. The invention discovers the application of the Flabelliferin B in preparing anti-tuberculosis drugs firstly; a completely new skeleton type is adopted and the activity on inhibiting the tuberculosis is extraordinarily strong, and the invention is impossible to be inspired by other compounds in any forms, therefore outstanding substantive features are achieved; and meanwhile, on the prevention and treatment of tuberculous infection, a significant progress is obviously made.

The invention discloses application of Isocycloartobiloxanthone in preparing a drug for treating tubercle bacilli. According to the situation that the morbidity of tuberculosis is high, mycobacterium tuberculosis multi-drug resistant strains occur, and the morbidity and the death rate of the tubercle bacilli are on the rise, it is found that the Isocycloartobiloxanthone has the activity of obviously inhibiting the tubercle bacilli, and a good application prospect is achieved.

The invention discloses an application of Houttuynoid B in the preparation of a medicament for resisting tubercle bacillus. Aiming at the current situation that the disease incidence and the mortality rate of tuberculosis have ascending trends due to high disease incidence of tuberculosis and the appearance of tubercle bacillus multiple drug-resistant strains at present, Houttuynoid B has the characteristic of obviously inhibiting the activity of tubercle bacillus and has good application prospect. The application of Houttuynoid B in the preparation of a medicament for resisting tubercle bacillus is firstly disclosed; since the skeleton type belongs to an entirely new skeleton type and the activity for inhibiting tubercle bacillus is previously unimagined high without any possibility of giving out revelation by other compounds, the application has outstanding substantial characteristics; and simultaneously, the application for preventing and treating tubercle bacillus infection is obviously advanced.

The invention discloses the applications of Polyflavanostilbene A in preparing an anti-tubercle bacillus medicine. Aimed at the current situation that the morbidity and mortality of tuberculosis are on the rise due to the high morbidity of tuberculosis and the appearance of multi-drug resistant strain of mycobacterium tuberculosis at present, the invention discovers that Polyflavanostilbene A has obvious activity in suppressing tubercle bacillus, and has good application prospects. The application of Polyflavanostilbene A in preparing an anti-tubercle bacillus medicine is disclosed for the first time; and since the skeleton type is a brand new one and the activity in suppressing tubercle bacillus is unexpectedly high, the possibility of any prompt given by other compounds does not exist, and prominent substantive features are provided and a remarkable progress in preventing and treating tubercle bacillus infection.

The invention discloses an application of Houttuynoid D in preparation of a tubercle bacillus resistant medicament. According to the current situation that the incidence and the mortality of tuberculosis rise due to high incidence of the conventional tuberculosis and appearance of multi-resistant strains of tubercle bacilli, the Houttuynoid D has the activity of remarkably inhibiting the tubercle bacilli and has a good application prospect. The invention discloses the application of the Houttuynoid D in preparation of the tubercle bacillus resistant medicament for the first time, the skeleton type belongs to a brand-new skeleton type, the Houttuynoid D has unexpected strong inhibiting activity on the tubercle bacilli, the probability of giving any revelation by other compounds does not exist, and the Houttuynoid D has predominant substantial characteristics and obviously makes a remarkable progress on prevention and treatment of tubercle bacillus infection.

The invention discloses an application of Houttuynoid D in preparation of a tubercle bacillus resistant medicament. According to the current situation that the incidence and the mortality of tuberculosis rise due to high incidence of the conventional tuberculosis and appearance of multi-resistant strains of tubercle bacilli, the Houttuynoid D has the activity of remarkably inhibiting the tubercle bacilli and has a good application prospect. The invention discloses the application of the Houttuynoid D in preparation of the tubercle bacillus resistant medicament for the first time, the skeleton type belongs to a brand-new skeleton type, the Houttuynoid D has unexpected strong inhibiting activity on the tubercle bacilli, the probability of giving any revelation by other compounds does not exist, and the Houttuynoid D has predominant substantial characteristics and obviously makes a remarkable progress on prevention and treatment of tubercle bacillus infection.

The invention discloses application of Lycojaponicumin C in preparation of an anti-tubercle bacillus drug. Aiming at the situation that at present, the tuberculosis morbidity is high, multi-drug-resistant strains of mycobacterium tuberculosis are present and accordingly the tuberculosis morbidity and mortality are on the rise, we find that the Lycojaponicumin C has remarkable tubercle bacillus inhabiting activity and good application prospect. The application of the Lycojaponicumin C in the preparation of the anti-tubercle bacillus drug is disclosed for the first time. Due to the fact that the skeleton type is a novel skeleton type and the high tubercle bacillus inhabiting activity of the Lycojaponicumin C is previously unimagined, the possibility that other compounds give any revelation does not exist, and the Lycojaponicumin C has outstanding substantive characteristics and meanwhile has a remarkable improvement in prevention and curing of tubercle bacillus infection obviously.

The invention discloses an application of Houttuynoid A in preparing medicines for inhibiting tubercle bacillus. The application of Houttuynoid A in preparing medicines for inhibiting tubercle bacillus aims at the current situation that high tuberculosis incidence and the appearance of multiple-resistant strains of tubercle bacillus result in the rising tendency in the incidence and mortality rate of tuberculosis, and Houttuynoid A is found to have remarkable tubercle bacillus inhibitory activity and good application prospect. The application of Houttuynoid A in preparing medicines for inhibiting tubercle bacillus is disclosed for the first time, has prominent substantive features and no any possibility for other compounds to give any inspiration, and simultaneously has remarkable progress when used for preventing and treating tubercle bacillus infection.

The invention discloses an application of a quinine compound in preparing anti-tubercle bacillus drugs. A structure general formula of the quinine compound of the invention is shown in a formula (1), wherein R is H or OH. In the invention, aiming to current situations that the current tuberculosis has high morbidity, and multidrug-resistant tuberculosis (TB) strains of tubercle bacillus occur so that the morbidity and mortality of the tuberculosis are in a rising trend, and according to characteristics of anti-tubercle bacillus and tolerance tubercle bacillus activities of the quinine compound, the quinine compound is used for preparing the anti-tubercle bacillus drugs. The quinine compound of the invention is derived from marine microorganisms, is easy to be extracted, has low cost and wide application prospect, and can be used for preparing the anti-tubercle bacillus drugs.

The invention discloses application of Lycojaponicumin B in the preparation of anti-mycobacterium tuberculosis drugs. Aiming at the phenomenon that at present, tuberculosis incidence is high and multi-drug resistant mycobacterium tuberculosis strains appear, so that the incidence and mortality rates of tuberculosis are on the rise, the invention discovers that the Lycojaponicumin B has remarkable activity of inhibiting mycobacterium tuberculosis, and has a good application prospect. The application of the Lycojaponicumin B in the preparation of the anti-mycobacterium tuberculosis drugs is disclosed for the first time. The Lycojaponicumin B has the advantages that the skeleton type belongs to an unprecedented skeleton type, and the inhibitory activity on mycobacterium tuberculosis is unexpectedly high, so that the probability that other compounds give enlightenments does not exist. The Lycojaponicumin B has an outstanding substantial characteristic, and meanwhile makes remarkable progress in preventing mycobacterium tuberculosis infection.

The invention discloses application of Houttuynoid C in preparing an anti-tubercle bacillus medicine. Aiming at the current situation that the morbidity and mortality of tuberculosis are on the rise due to the high morbidity of tuberculosis and the appearance of multi-drug resistant strain of mycobacterium tuberculosis at present, the invention discovers that Houttuynoid C has obvious activity in suppressing tubercle bacillus and has good application prospects. The application of Houttuynoid C in preparing an anti-tubercle bacillus medicine is disclosed for the first time; and since the skeleton type is a brand new one and the activity in suppressing tubercle bacillus is unexpectedly strong, the possibility of any other compound offering any inspiration does not exist, outstanding substantial characteristics are obtained, and an obvious progress is made in preventing and treating tubercle bacillus infection.

The invention discloses application of Lycojaponicumin A in preparation of an anti-tubercle bacillus drug. Aiming at the situation that at present, the tuberculosis morbidity is high, multi-drug-resistant strains of mycobacterium tuberculosis are present and accordingly the tuberculosis morbidity and mortality are on the rise, we find that the Lycojaponicumin A has remarkable tubercle bacillus inhabiting activity and good application prospect. The application of the Lycojaponicumin A in the preparation of the anti-tubercle bacillus drug is disclosed for the first time. Due to the fact that the skeleton type is a novel skeleton type and the high tubercle bacillus inhabiting activity of the Lycojaponicumin A is previously unimagined, the possibility that other compounds give any revelation does not exist, and the Lycojaponicumin A has outstanding substantive characteristics and meanwhile has a remarkable improvement in prevention and curing of tubercle bacillus infection obviously.